Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994106 | 0.84 | RXRA (0.36) | RARGRXRAPPARGALDH1A1KDM4E | |
| SCHEMBL6346410 | 0.83 | RXRA (0.34) | RARGRXRAPPARG | |
| SCHEMBL18634582 | 0.82 | RXRA (0.42) | RARGRXRAPPARGALDH1A1TSHR | |
| SCHEMBL7195524 | 0.81 | RARG (0.32) | RARGRXRAPPARGPTGS2ALOX5 | |
| SCHEMBL23802016 | 0.81 | PRKDC (0.44) | ALDH1A1TSHRTDP1KDM4ECA1 | |
| SCHEMBL18556291 | 0.81 | CYP3A4 (0.39) | RARGRXRAPPARGALDH1A1TSHR | |
| SCHEMBL16829498 | 0.81 | ALDH1A1 (0.36) | RARGRXRAPPARGALDH1A1TSHR | |
| SCHEMBL1542282 | 0.81 | ERN1 (0.47) | ALDH1A1TSHRTDP1KDM4ETNFRSF1A | |
| SCHEMBL6766393 | 0.81 | MCL1 (0.41) | ALDH1A1TSHRTDP1KDM4ETNFRSF1A | |
| SCHEMBL19124038 | 0.81 | CYP3A4 (0.39) | RARGRXRAPPARGALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666910-A | Organic metal platinum complex, preparation method thereof and organic electroluminescent device comprising organic metal platinum complex | 吉林奥来德光电材料股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-10196338-B2 | Chiral diamine compounds for the preparation of chiral alcohols and chiral amines | UNIVERSITY COLLEGE DUBLIN (IE) | 2019-02-05 | — | — | US | disclosed |
| EP-2794620-B1 | BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS | NAT UNIV SINGAPORE (SG) | 2017-11-15 | — | — | EP | disclosed |
| US-20170204036-A1 | CHIRAL DIAMINE COMPOUNDS FOR THE PREPARATION OF CHIRAL ALCOHOLS AND CHIRAL AMINES | UNIVERSITY COLLEGE DUBLIN (IE) | 2017-07-20 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423395-B2 | Fluorescent cell cycle probe having M-phase specificity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423395-B2 | Fluorescent cell cycle probe having M-phase specificity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004026315-A1 | SUBSTITUTED KETOPHOSPHONATE COMPOUNDS HAVING BONE ANABOLIC ACTIVITY | ILEX ONCOLOGY RESEARCH, SARL (CH) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026243-A2 | THERAPEUTIC USES OF LINEAR KETOPHOSPHONATES | ILEX ONCOLOGY RESEARCH, SARL (CH) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026242-A2 | SUBSTITUTED KETOPHOSPHONATE INHIBITORS OF TUMOR CELL PROLIFERATION | ILEX ONCOLOGY RESEARCH, SARL (CH) | 2004-04-01 | — | — | WO | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
| CN-1229407-A | Diaryl compounds and pharmaceutical and cosmetic compositions containing them | CIRD GALDERMA (FR) | 1999-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | RARG 1227/4885RXRA 1434/4885PPARG 2848/4885 |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | RARG 136/4885RXRA 37/4885PPARG 418/4885 |
| US-10196338-B2 | Chiral diamine compounds for the preparation of chiral alcohols and chiral amines | ADH1C, ADH1A, ADH5 | RARG 540/4885RXRA 1732/4885PPARG 1249/4885 |
| US-20170204036-A1 | CHIRAL DIAMINE COMPOUNDS FOR THE PREPARATION OF CHIRAL ALCOHOLS AND CHIRAL AMINES | ADH1C, ADH1A, ADH5 | RARG 557/4885RXRA 1655/4885PPARG 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.